Observational studySexually transmitted diseases2025
High Incidence of Curable Sexually Transmitted Infections Among Persons Accessing Oral Preexposure Prophylaxis at an Integrated Sexually Transmitted Infection/Preexposure Prophylaxis Clinic in Lilongwe, Malawi.
Observational study in Sexually transmitted diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05307991 (Integrating Enhanced HIV Pre-exposure Prophylaxis Into a Sexually Transmitted Infection Clinic in Lilongwe), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrating Enhanced HIV Pre-exposure Prophylaxis Into a Sexually Transmitted Infection Clinic in Lilongwe
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundUnderstanding the burden of incident sexually transmitted infections (STIs) among persons in Eastern and Southern Africa after initiating HIV preexposure prophylaxis (PrEP) is critical to allocate scarce STI testing and HIV prevention resources.
methodsParticipants were recruited from an STI clinic in Lilongwe, Malawi (March-December 2022). Eligibility reflected oral PrEP eligibility per contemporary guidelines, limited to persons seeking STI services. We enrolled 3 groups: "index participants" who initiated PrEP, "PrEP-eligible decliners" who declined PrEP, and PrEP-initiating "referred partners" referred by index participants. Surveys and PrEP use assessments were conducted at baseline and at 1, 3, and 6 months; Chlamydia trachomatis, Neisseria gonorrhoeae, and syphilis testing done at baseline and at 3 and 6 months. A subset of participants completed in-depth interviews that were thematically analyzed.
resultsWe enrolled 238 participants (174 index, 37 PrEP-eligible decliners, 27 referred partners); most were male (58%), and the median age was 27 years (interquartile range, 22-31 years). Forty-seven incident STIs were identified during 89.3 person-years (py) of follow-up (52.6/100 py). Men had a higher incidence versus women (55.8/100 py vs. 48.6/100 py). Index participants had the highest STI incidence (61.3/100 py), compared with PrEP-eligible decliners (26.4/100 py) and referred partners (27.1/100 py). Most incident infections were asymptomatic. Nearly all 27 interviewed participants described an STI as related to perceived HIV risk and need for PrEP.
conclusionsIncident, asymptomatic STIs in the 6 months after PrEP initiation were common. Testing of STI contextualizes perceived HIV risk and may encourage PrEP persistence. Integrating bacterial STI testing within PrEP care may reduce transmission via expedient treatment and should be considered alongside PrEP program expansion.Clinical Trial Number: NCT05307991 ( https://clinicaltrials.gov/ct2/show/NCT05307991 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.